Certara Products - Simcyp Archives | Page 20 of 23

Blog

Inside the Mind of Pharmacometrics Pioneer, Professor Malcolm Rowland

Officially, Prof. Malcolm Rowland has retired. This scientific pioneer has been helping lay the foundation…

CertaraFebruary 23, 2016

Blog

Conventional & Mechanistic IVIVC: Complementary or Clashing Methods?

An IVIVC (in vitro-in vivo correlation) is a mathematical relationship that predicts key pharmacokinetic parameters…

CertaraFebruary 9, 2016

Publication

A Bottom-up Whole-body Physiologically-based Pharmacokinetic Model to Mechanistically Predict Tissue Distribution and the Rate of Subcutaneous Absorption of Therapeutic Proteins

CertaraJanuary 1, 2016

Blog

Modeling the Influence of Ethnicity on Drug Disposition

Ever noticed how people from different ethnic backgrounds respond differently to drugs? For example, you…

CertaraNovember 23, 2015

Publication

Interplay of Metabolism and Transport in Determining Oral Drug Absorption and Gut Wall Metabolism: A Simulation Assessment Using the “Advanced Dissolution, Absorption, Metabolism (ADAM)” Model

Bioavailability of orally administered drugs can be influenced by a number of factors including release…

CertaraNovember 1, 2015

Blog

How to Optimize Your Drug Label Using Modeling and Simulation Technology

As a trained pharmacist and scientist, I think a lot about patient care and how…

CertaraSeptember 29, 2015

Blog

100 Articles That Will Help You Understand PBPK Modeling & Simulation

As a company with a strong academic foundation, our scientists actively publish the results of…

CertaraJuly 28, 2015

Blog

How to Revamp Your Approach to Conventional IVIVC Models

An IVIVC (in vitro-in vivo correlation) is a predictive mathematical model describing the relationship between…

CertaraJuly 21, 2015

Publication

Application of Permeability-limited Physiologically-based Pharmacokinetic Models: Part I—Digoxin Pharmacokinetic Incorporating P-glycoprotein-mediated Efflux

A prerequisite for the prediction of the magnitude of P-glycoprotein (P-gp)-mediated drug-drug interactions between digoxin…

CertaraSeptember 1, 2013

Publication

Application of Permeability-limited Physiologically-based Pharmacokinetic Models: Part II—Prediction of P-glycoprotein Mediated Drug-drug Interactions with Digoxin

Digoxin is the recommended substrate for assessment of P-glycoprotein (P-gp)-mediated drug-drug interactions (DDIs) in vivo.…

CertaraSeptember 1, 2013

Certara Products – Simcyp

Inside the Mind of Pharmacometrics Pioneer, Professor Malcolm Rowland

Conventional & Mechanistic IVIVC: Complementary or Clashing Methods?

A Bottom-up Whole-body Physiologically-based Pharmacokinetic Model to Mechanistically Predict Tissue Distribution and the Rate of Subcutaneous Absorption of Therapeutic Proteins

Modeling the Influence of Ethnicity on Drug Disposition

Interplay of Metabolism and Transport in Determining Oral Drug Absorption and Gut Wall Metabolism: A Simulation Assessment Using the “Advanced Dissolution, Absorption, Metabolism (ADAM)” Model

How to Optimize Your Drug Label Using Modeling and Simulation Technology

100 Articles That Will Help You Understand PBPK Modeling & Simulation

How to Revamp Your Approach to Conventional IVIVC Models

Application of Permeability-limited Physiologically-based Pharmacokinetic Models: Part I—Digoxin Pharmacokinetic Incorporating P-glycoprotein-mediated Efflux

Application of Permeability-limited Physiologically-based Pharmacokinetic Models: Part II—Prediction of P-glycoprotein Mediated Drug-drug Interactions with Digoxin

Newsletter sign up

Quick links

Solutions

Contact